Previous 10 | Next 10 |
2024-03-08 02:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...
2024-02-28 03:49:01 ET Altimmune (NASDAQ: ALT) stock price continued its short squeeze this week, soaring to a high of $14.52, its highest point since February 6th last year. The company’s stock surged by more than 580% from its lowest level in 2023. This surge has brought its to...
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
2024-02-26 16:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-14 12:09:33 ET More on Altimmune Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment Thoroughly Derisked, Altimmune Is Now A Great Buy Altimmune: Don't Buy The GLP-1 Move-Up Altimmune skids after Kerrisdale Capital short report ...
NEW YORK, NY / ACCESSWIRE / February 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Altimmune, Inc. ("Altimmune" or "the Company") (NASDAQ:ALT). Investors who purchased Altimmune securities are encouraged to obtain additional inform...
2024-02-14 08:52:06 ET Altimmune (NASDAQ: ALT) share price experienced a significant decline on Tuesday following a report by Kerrisdale Capital, in which the investment firm disclosed a short position in the company’s shares. Kerrisdale’s critical analysis suggests th...
2024-02-13 10:38:09 ET More on Altimmune Altimmune's Pemvidutide Lacks Differentiation In Obesity Treatment Thoroughly Derisked, Altimmune Is Now A Great Buy Altimmune: Don't Buy The GLP-1 Move-Up Altimmune weight-loss drug performed better than rivals, says ...
2024-02-11 22:43:10 ET Summary Altimmune's stock surged after revealing promising obesity treatment data for pemvidutide, a GLP-1/glucagon agonist, despite existing competition. Pemvidutide demonstrated dose-dependent weight loss in Phase 2, but high adverse event rates, especiall...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Comp...
NEW YORK, May 10, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Comp...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...